Turning necrosis into apoptosis: The exacting task that can enhance survival

American Heart Journal

Volumn 148, Issue 2, 2004, Pages 196-199

  Chen Scarabelli, Carol ^a   Scarabelli, Tiziano M ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CORTICOSTEROID; FLUINDOSTATIN; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UROCORTIN;

APOPTOSIS; CELL FUNCTION; CLINICAL TRIAL; EDITORIAL; HEART INFARCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MORTALITY; NECROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL; TREATMENT PLANNING;

ADENOSINE TRIPHOSPHATE; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; CORTICOTROPIN-RELEASING HORMONE; CYTOKINES; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; NECROSIS; NEUTROPHILS;

EID: 4143084936     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.03.030     Document Type: Editorial

References (41)

1. Mehta J.L., Li D.Y. Inflammation in ischemic heart disease response to tissue injury or a pathetic villain? Cardiovasc Res. 2:1999;291-299
2. Maroko P.R., Carpenter C.B., Chiariello M., et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest. 3:1978;661-670
3. Shappell S.B., Taylor A.A., Hughes H., et al. Comparison of antioxidant and nonantioxidant lipoxygenase inhibitors on neutrophil function implications for pathogenesis of myocardial reperfusion injury. J Pharmacol Exp Ther. 2:1990;531-538
4. Romson J.L., Hook B.G., Kunkel S.L., et al. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 5:1983;1016-1023
5. Mullane K.M., Read N., Salmon J.A., et al. Role of leukocytes in acute myocardial infarction in anesthetized dogs relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther. 2:1984;510-522
6. Engler RL, Dahlgren MD, Morris DD, et al. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol 1986;251(2 Pt 2):H314-23
7. Jolly S.R., Kane W.J., Bailie M.B., et al. Canine myocardial reperfusion injury its reduction by the combined administration of superoxide dismutase and catalase. Circ Res. 3:1984;277-285
8. Giugliano G.R., Giugliano R.P., Gibson C.M., et al. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol. 91:2003;1055-1059
9. Hafezi-Moghadam A., Simoncini T., Yang E., et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 8:2002;473-479
10. Ko D., Wang Y., Berger A.K., et al. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J. 143:2002;475-481
11. Griselli M., Herbert J., Hutchinson W.L., et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 190:1999;1733-1740
12. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168
13. Kuller L.H., Tracy R.P., Shaten J., et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 144:1996;537-547
14. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979
15. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99:1999;237-242
16. Biasucci L.M., Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 94:1996;874-877
17. Anguera I., Miranda-Guardiola F., Bosch X., et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 144:2002;811-817
18. Heeschen C., Dimmeler S., Hamm C.W., et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 107:2003;2109-2114
19. Tiefenbacher C.P., Kapitza J., Dietz V., et al. Reduction of myocardial infarct size by fluvastatin. Am J Physiol Heart Circ Physiol. 285:2003;H59-64
20. Weisman H.F., Bush D.E., Mannisi J.A., et al. Cellular mechanism of myocardial infarct expansion. Circulation. 78:1988;186-201
21. Jugdutt B.I., Michorowski B.L. Role of infarct expansion in rupture of ventricular septum after acute myocardial infarction a two dimensional echocardiographic study. Clin Cardiol. 10:1987;641-652
22. Weisman H.F., Healy B. Myocardial infarct expansion, infarct extension, and reinfarction pathophysiologic concepts. Prog Cardiovasc Dis. 30:1987;73-110
23. Schuster E.H., Bulkley B.H. Expansion of transmural myocardial infarction a pathophysiologic feature in cardiac rypture. Circulation. 60:1979;1532
24. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 107:2003;690-695
25. Vaughan J., Donaldson C., Bittencourt J., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292
26. Petraglia F., Florio P., Gallo R., et al. Human placenta and fetal membranes express human urocortin mRNA and peptide. J Clin Endocrinol Metab. 81:1996;3807-3810
27. Kageyama K., Bradbury M.J., Zhao L., et al. Urocortin messenger ribonucleic acid tissue distribution in the rat and regulation in thymus by lipopolysaccharide and glucocorticoids. Endocrinology. 140:1999;5651-5658
28. Oki Y., Iwabuchi M., Masuzawa M., et al. Distribution and concentration of urocortin, and effect of adrenolectomy on its content in rat hypothalamus. Life Sci. 62:1998;807-812
29. Okosi A., Brar B.K., Chan M., et al. Expression and protective effects of urocortin in cardiac myocytes. Neuropeptides. 32:1998;167-171
30. Brar B.K., Jonassen A.K., Stephanou A., et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem. 275:2000;8508-8514
31. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002;283:H1481-8
32. Scarabelli T.M., Pasini E., Stephanou A., et al. Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia/reperfusion. J Am Coll Cardiol. 40:2002;155-161
33. Brar B.K., Stephanou A., Knight R., et al. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol. 34:2002;483-492
34. Brar B.K., Railson J., Stephanou A., et al. Urocortin increases the expression of heat shock protein 90 in rat cardiac myocytes in a MEK1/2-dependent manner. J Endocrinol. 172:2002;283-293
35. Lawrence K.M., Chanalaris A., Scarabelli T., et al. KATP channel gene expression is induced by urocortin and mediates its cardioprotective effects. Circulation. 106:2002;1556-1562
36. Scarabelli TM, Pasini E, Ferrari G, et al. Warm blood cardioplegic arrest induces mitochondrial-mediated cardiomyocyte apoptosis associated with increased urocortin expression in viable cells. J Thorac Cardiov Surg 2004 (in press)
37. Liu Y., Sato T., Seharaseyon J., et al. Mitochondrial ATP-dependent potassium channels viable candidate effectors of ischemic preconditioning. Ann N Y Acad Sci. 874:1999;27-37
38. Lawrence K.M., Scarabelli T.M., Turtle L., et al. Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB J. 17:2003;2313-2315
39. Leist M., Single B., Castoldi A.F., et al. Intracellular ATP concentration a switch deciding between apoptosis and necrosis. J Exp Med. 185:1997;1481-1486
40. Bradbury D.A., Simmons T.D., Slater K.J., et al. Measurement of the ADP ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods. 240:2000;79-92
41. Nayler W.G., Panogiotopoulos S., Elz J.S., et al. Fundamental mechanism of action of calcium antagonist in myocardial ischemia. Am J Cardiol. 59:1987;75-83B